Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ODC1 | P11926 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009938 | 0.84 | ACACB (0.47) | ACACBACACAODC1KDM4ELMNA | |
| SCHEMBL30017124 | 0.76 | ACACB (0.38) | ACACBACACATSHRALDH1A1CYP2D6 | |
| SCHEMBL7388370 | 0.76 | ODC1 (0.38) | ACACBACACAALDH1A1ODC1CYP2D6 | |
| SCHEMBL3749967 | 0.73 | CA2 (0.35) | ACACBACACATSHRALDH1A1CYP2D6 | |
| SCHEMBL11420379 | 0.70 | HMGCR (0.34) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL10695323 | 0.70 | BLM (0.35) | ACACBACACABLM | |
| SCHEMBL5474459 | 0.69 | ALDH1A1 (0.42) | ACACBACACATSHRALDH1A1CYP2D6 | |
| SCHEMBL10315785 | 0.69 | — | — | |
| SCHEMBL1010543 | 0.68 | ACACB (0.53) | ACACBACACAALDH1A1MAPT | |
| SCHEMBL1902516 | 0.67 | ALDH1A1 (0.40) | TSHRALDH1A1CYP2D6CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | APOSENSE LTD. (IL) | 2011-10-20 | — | — | US | disclosed |
| US-7947253-B2 | compounds such as 2-methyl-2(3-fluoropropyl)-malonic Acid that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets | APOSENSE LTD. (IL) | 2011-05-24 | — | — | US | disclosed |
| US-20100035296-A1 | COMPOUNDS AND METHODS FOR DETECTION OF CELLS | APOSENSE LTD. (IL) | 2010-02-11 | — | — | US | disclosed |
| EP-2121042-A2 | COMPOUNDS AND METHODS FOR DETECTION OF CELLS | Aposense Ltd. (IL) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008081447-A2 | COMPOUNDS AND METHODS FOR DETECTION OF CELLS | APOSENSE LTD. (IL) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035296-A1 | COMPOUNDS AND METHODS FOR DETECTION OF CELLS | CASP3, BAX, BAD | ACACB 328/4885ACACA 393/4885TSHR 4649/4885 |
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | ANXA5, SELPLG, ANXA6 | ACACB 3279/4885ACACA 3736/4885TSHR 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.